Open AccessAmbrisentan for the Treatment of Pulmonary Arterial Hypertension
Author(s) -
Nazzareno Galiè,
Horst Olschewski,
Ronald J. Oudiz,
Ferrán Torres,
Adaani Frost,
Hossein A. Ghofrani,
David B. Badesch,
Michael D. McGoon,
Vallerie V. McLaughlin,
Ellen B. Roecker,
Michael J. Gerber,
Christopher Dufton,
Brian L. Wiens,
Lewis J. Rubin
Publication year - 2008
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.107.742510
Subject(s) - ambrisentan , medicine , placebo , pulmonary hypertension , clinical endpoint , cardiology , randomized controlled trial , urology , endothelin receptor , bosentan , receptor , alternative medicine , pathology
Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom